Regression of DMBA-induced breast carcinoma following ovariectomy is associated with increased expression of genes encoding Insulin-like Growth Factor binding proteins

International Journal of Oncology

Volumn 14, Issue 5, 1999, Pages 987-990

  Nickerson, Tara ^a   Zhang, Jianchun ^a   Pollak, Michael ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Cancer Prevention Research Unit   (Canada)

Author keywords

Breast cancer; Insulin like growth factor binding proteins; Insulin like growth factor I

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENETICS; METABOLISM; NORTHERN BLOTTING; OVARIECTOMY; RAT; SPRAGUE DAWLEY RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BLOTTING, NORTHERN; FEMALE; GENE EXPRESSION; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MAMMARY NEOPLASMS, ANIMAL; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 0033125587     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.5.987     Document Type: Article

References (32)

1. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252, 1995.
2. Sepp-Lorenzino L: Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 47: 235-253, 1998.
3. Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8: 45-62, 1997.
4. Pratt SE and Pollak M: Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of IGF binding proteins in conditioned media. Cancer Res 53: 5193-5198, 1993.
5. Huynh HT, Yang XF and Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016-1021, 1996.
6. Huynh HT, Yang XF and Pollak M: A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 7: 1501-1506, 1996.
7. Oh Y, Mullers HL, Ng L and Rosenfeld RG: Transforming growth factor-β-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 270: 13589-13592, 1995.
8. Gucev ZS, Oh Y, Kelley KM and Rosenfeld RG: Insulin-like growth factor binding protein 3 mediates retinoic acid and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells. Cancer Res 56: 1545-1550, 1996.
9. Rozen F, Yang X, Huynh HT and Pollak M: Antiproliferative action of vitamin-D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 89: 652-656, 1997.
10. Rozen F, Zhang J and Pollak M: Antiproliferation action of tumor necrosis factor-alpha on MCF-7 breast cancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 13: 865-869, 1998.
11. Lopez-Otin C and Diamandis P: Breast and prostate cancer: an analysis of common epidemiology, genetic, and biochemical features. Endocr Rev 19: 365-396, 1998.
12. Tonner E, Quarrie L, Travers M, Barber M, Logan A, Wilde C and Flint D: Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis? Prog Growth Factor Res 6: 409-414, 1995.
13. Tonner E, Barber MC, Travers MT, Logan A and Flint DJ: Hormonal control of insulin-like growth factor binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 138: 5101-5107, 1997.
14. Rajah R, Valentinis B and Cohen P: Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272: 12181-12188, 1997.
15. Nickerson T, Huynh H and Pollak M: Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 237: 690-693, 1997.
16. Nickerson T, Pollak M and Huynh H: Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. Endocrinology 139: 807-810, 1998.
17. Shimasaki S and Ling N: Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1,-2,-3,-4,-5 and -6). Prog Growth Factor Res 3: 243-266, 1991.
18. Wilson JW, Wakeling AE, Morris ID, Hickman JA and Dive C: MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage. Int J Cancer 61: 502-508, 1995.
19. Warri AM, Huovinen RL, Laine AM, Martikainen PM and Harkonen PL: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412-1418, 1993.
20. Kyprianou N, English HF, Davidson NE and Isaacs JT: Programmed cell death during regression of the MCF7 human breast cancer following estrogen ablation. Cancer Res 51: 162-166, 1991.
21. Wang TT and Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487-2489, 1995.
22. Huovinen R, Warri A and Collan Y: Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene. Int J Cancer 55: 685-691, 1993.
23. Guenette RS, Corbeil HB, Leger J, Wong K, Mezl V, Mooibroek M and Tenniswood M: Induction of gene expression during involution of the lactating mammary gland of the rat. J Mol Endocrinol 12: 47-60, 1994.
24. Huovinen R and Collan Y: Cell loss in dimethylbenz(a)-anthracene-induced rat mammary carcinoma treated with toremifene and ovariectomy. Tumour Biol 15: 345-353, 1994.
25. Jordan VC and Allen KE: Evaluation of the antitumor activity of the non-steroidal antiestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239-251, 1980.
26. Oh Y, Muller HL, Lamson G and Rosenfeld RG: Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. J Biol Chem 268: 14964-14971, 1993.
27. Oh Y, Muller HL, Pham H and Rosenfeld RG: Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268: 26045-26048, 1993.
28. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE and Pollak M: Circulating, concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998.
29. Chan JM, Stampfer MK, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennckens CH and Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998.
30. Chen WY, Chen NY, Yum J, Washer TE and Kopchick JJ: In vitro and in vivo studies of antagonistic effects of human growth hormone analogues. J Biol Chem 269: 15892-15897, 1994.
31. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z and Schally AV: Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 91: 12298-12302, 1994.
32. Pollak M, Polychronakos C and Guyda H: Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9: 889-891, 1989.